Spots Global Cancer Trial Database for recurrent acute lymphoblastic leukemia

Every month we try and update this database with for recurrent acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	NCT05418088	Recurrent Acute... Recurrent B Acu... Recurrent B-Cel... Recurrent Chron... Recurrent High ... Recurrent Indol... Recurrent Non-H... Recurrent Trans... Refractory Acut... Refractory B Ac... Refractory B-Ce... Refractory Chro... Refractory High... Refractory Indo... Refractory Non-... Refractory Tran...	Anti-CD19/CD20/... Cyclophosphamid... Fludarabine Pho...	18 Years -	Ohio State University Comprehensive Cancer Center
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	NCT01822509	Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	NCT02706392	Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu...	Laboratory Biom... ROR1 CAR-specif...	18 Years -	Fred Hutchinson Cancer Center
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	NCT03263572	Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22)	Blinatumomab Cytarabine Methotrexate Ponatinib	18 Years -	M.D. Anderson Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia	NCT03136146	Recurrent Acute... Recurrent Adult... Recurrent Burki... Recurrent Burki... Recurrent Child... Recurrent High ... Refractory Acut... Refractory Burk... Refractory Burk... Refractory High... Refractory Lymp...	Bortezomib Clofarabine Cyclophosphamid... Dexamethasone Etoposide Ofatumumab Pegfilgrastim Rituximab Vincristine Sul...	15 Years -	M.D. Anderson Cancer Center
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.	NCT00390793	Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22)	Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine	18 Years -	M.D. Anderson Cancer Center
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	NCT03263572	Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22)	Blinatumomab Cytarabine Methotrexate Ponatinib	18 Years -	M.D. Anderson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	NCT02220985	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra...	- 60 Years	Fred Hutchinson Cancer Center
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	NCT03576547	Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22)	Dexamethasone Ponatinib Hydro... Rituximab Venetoclax	18 Years -	M.D. Anderson Cancer Center
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	NCT03132454	Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut...	Decitabine Dexamethasone Palbociclib Sorafenib	15 Years -	M.D. Anderson Cancer Center
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	NCT03576547	Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22)	Dexamethasone Ponatinib Hydro... Rituximab Venetoclax	18 Years -	M.D. Anderson Cancer Center
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	NCT03132454	Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut...	Decitabine Dexamethasone Palbociclib Sorafenib	15 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia	NCT03512405	CD19 Positive Philadelphia Ch... Recurrent Acute... Refractory Acut...	Blinatumomab Laboratory Biom... Pembrolizumab	18 Years -	City of Hope Medical Center
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	NCT02706392	Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu...	Laboratory Biom... ROR1 CAR-specif...	18 Years -	Fred Hutchinson Cancer Center
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT04752163	Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Chro... Refractory Myel...	DS-1594b Azacitidine Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Leucovorin Mesna Methotrexate Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole	18 Years -	M.D. Anderson Cancer Center
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia	NCT03094611	CD22 Positive Recurrent Acute... Refractory Acut...	Inotuzumab Ozog...	12 Years -	M.D. Anderson Cancer Center
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	NCT03128034	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Mixe... Mixed Phenotype...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Pretargeted Rad... Total-Body Irra...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	NCT05192889	Refractory Acut... Relapsed Acute ...	Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation	4 Years - 30 Years	St. Jude Children's Research Hospital
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.	NCT00390793	Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22)	Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine	18 Years -	M.D. Anderson Cancer Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	NCT05192889	Refractory Acut... Relapsed Acute ...	Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation	4 Years - 30 Years	St. Jude Children's Research Hospital
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia	NCT02551718	Recurrent Acute... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Refractory Acut...	Chemosensitivit... Cytology Specim... Gene Expression... Genetic Variati... In Vitro Sensit...	3 Years -	University of Washington
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: